{'fraction_non_alphanumeric': 0.03417634996582365, 'fraction_numerical': 0.02323991797676008, 'mean_word_length': 5.310344827586207, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Ibrutinib + Cirmtuzumab in Patients With CLL/SLL or Mantle Cell Lymphoma

T he transmembrane protein ROR1 is one member of the receptor tyrosine kinase-like orphan receptor family (the other member is ROR2). This embryonic protein, which is not normally expressed in postpartum tissues, has been observed in several different malignancies, including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL) (Protein & Cell 2014;5(7):496-502). Because of the differing expression between healthy adult and cancer cells, this has been employed as a therapeutic strategy. In particular, the ROR1-targeting monoclonal antibody cirmtuzumab is currently being evaluated in a clinical setting among patients with a variety of malignancies. One particularly interesting clinical study is a phase I/II trial (NCT03088878) that is evaluating the combination of the Bruton’s tyrosine kinase inhibitor ibrutinib plus cirmtuzumab in patients with CLL/SLL or MCL. One of the lead clinicians on this study is Michael Choi, MD, hematologist and medical oncologist at University of California San Diego School of Medicine and Moores Cancer Center. Regarding their safety findings, Choi stated, “We were pleased to see there were no new safety signals with this particular combination; no dose-limiting toxicities were observed.” Choi presented results from parts 1 and 2 of this 3-part study at the 2019 ASH Annual Meeting (Abstract 1755).